FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)

Completed · Phase 2

Conditions studied: Primary Focal Segmental Glomerulosclerosis

In brief

This is a multicenter, open label, randomized study investigating two dose titration regimens of CXA-10 in subjects at least 18 years of age with primary FSGS. The study will be performed at approximately 25 study centers across the United States of America (USA). The recruitment period is anticipated to be up to approximately 16 months. Approximately 30 subjects will be randomized to ensure 26 subjects complete the study. An optional 9 month open label is available

Key facts

Study ID

NCT03422510

Run by

Complexa, Inc.

People needed

33

Starts

2018-04-15

Expected to finish

2020-07-31

Last updated by the study team

2020-08-03

Who can join

Age: 13 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• have a diagnosis of primary FSGS confirmed with biopsy.
• eGFR or 24-hour creatinine clearance ≥ 40 mL/min/1.73 m2 at Screening.
• The subject has a Up/c ratio ≥ 2 g protein/g creatinine based on a 24 hour urine sample collected during Screening (one 24-hour collection between Day -30 and Day -8).
• Unless there is an allergy or intolerance, subject must be on an ACEi and/or ARB regimen for a minimum of 4 weeks prior to their screening Up/c assessment. The ACEi and/or ARB regimen must be stable for a minimum of 2 weeks prior to screening Up/c assessment (and there are no plans to change the ACEi/ARB regimen over the course of the study).
• If receiving simvastatin containing products: simvastatin (Zocor), Vytorin, or any other combination therapy containing simvastatin, the simvastatin dose should not exceed 20 mg/day.
• Non-pregnant, non-lactating, female of childbearing potential who agrees to use a reliable method of contraception or female is of non-childbearing potential defined as surgically sterile (hysterectomy or bilateral tubal ligation) or post-menopausal.

You may not qualify if…

• The subject has collapsing variant of FSGS on renal biopsy.
• The subject has secondary FSGS.
• The subject has diabetic nephropathy.
• The subject has any other form of acquired (including biopsy proven obesity-induced FSGS) or hereditary glomerular nephropathy.
• The subject has a prolonged QTcF interval.
• The subject is hypertensive.
• The subject has a history of clinically significant cardiovascular events, arrhythmias, recurrent fainting, palpitations, or family history of congenital prolonged QT syndromes or sudden unexpected death due to a cardiac reason.
• The subject has any known bleeding disorders or significant active peptic ulceration in the opinion of the investigator that precludes enrollment into this study.
• The subject has clinically significant anemia in the opinion of the investigator that precludes enrollment into this study.
• The subject has a history of any primary malignancy, including a history of melanoma or suspicious undiagnosed skin lesions, with the exception of the following:
• Basal cell or squamous cell carcinomas of the skin,
• Cervical carcinoma in situ,
• Other malignancies curatively treated and with no evidence of disease for at least 5 years, or
• Prostate cancer which is not currently or expected, during the study, to undergo radiation therapy, chemotherapy, and/or surgical intervention, or to initiate hormonal treatment.
• The subject has a history of organ transplantation.
• The subject has a history of HIV.
• At the time of Screening (Visit 1), the subject has any co-existing disease or condition.
• Since the time of presentation of symptoms/diagnosis of FSGS: the subject has received systemic (oral or parenteral) high-dose, long-term corticosteroid therapy (prednisone or alternative glucocorticoid) to treat kidney disease
• Subject has a history of immunosuppressant therapy (calcineurin inhibitors, rituximab, or other non-steroid immunosuppressants).
• The subject has a history of herbal or natural medication use (including fish oil) within 2 weeks or 5 half-lives, whichever is longer, prior to Baseline
• The subject is currently taking a drug that may affect the measurement of serum creatinine (e.g. cimetidine, Bactrim, Pyridium).
• The subject is currently taking a newly prescribed drug or new prescription for an increased dose of an existing drug that is known to prolong the QTc interval and has been associated with Torsades de pointes (a list is provided in Appendix H). Note: Stable doses of these drugs are permitted (i.e., subject has received the same dose and regimen for at least 30 days prior to Screening [Visit 1] with no anticipated changes to the dose or regimen during the study).
• The subject is currently taking endothelin receptor antagonists, dimethyl fumarate (Tecfidera™), orlistat, fibrates (fenofibrate, bezafibrate, gemfibrozil and ciprofibrate), niacin or lomatapide.
• The subject has any of the following abnormal laboratories at Screening:
• Serologic evidence of HIV, hepatitis B, or hepatitis C based on HIV antibody, HBsAg, and HCV Ab,

Where it is running

• Alabama Neurology Consultants — Huntsville, Alabama, United States
• Cedars Sinai Medical Center — Los Angeles, California, United States
• Stanford University — Palo Alto, California, United States
• A.I. duPont Hospital for Children — Wilmington, Delaware, United States
• University of Miami — Miami, Florida, United States
• Nephrology Associates of Northern Illinois and Indiana (NANI) — Chicago, Illinois, United States
• Northwest Louisiana Nephrology — Shreveport, Louisiana, United States
• Kidney Care and Transplant Services of New England — Springfield, Massachusetts, United States
• University of Michigan — Ann Arbor, Michigan, United States
• St. Clair Nephrology Research — Roseville, Michigan, United States
• Clinical Research Consultants-KCMO — Kansas City, Missouri, United States
• Albert Einstein College of Medicine, Montefiore — The Bronx, New York, United States
• Metrolina Nephrology Associates — Charlotte, North Carolina, United States
• Levine Children's Hospital — Charlotte, North Carolina, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• Northeast Clinical Research Center (NCRC) — Bethlehem, Pennsylvania, United States
• University of Pennsylvania — Philadelphia, Pennsylvania, United States
• Nephrology Associates — Franklin, Tennessee, United States
• Texas Tech — Amarillo, Texas, United States
• Renal Disease Research Institute — DeSoto, Texas, United States
• El Paso Medical Research — El Paso, Texas, United States
• Virginia Commonwealth University — Richmond, Virginia, United States
• The Polyclinic — Seattle, Washington, United States
• Providence Sacred Heart Medical Center and Children's Hospital — Spokane, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.